Search

Displaying results 1471 - 1480 of 9325 in total
  1. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure … [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

  2. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. … By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the

  3. Drug

    Atorvastatin

    go.drugbank.com/drugs/DB01076
    ApprovedInvestigational

    By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. … More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid.

    Mixtures: EZETIMIBE E ATORVASTATINA DOC, EZETIMIBE E ATORVASTATINA DOC
  4. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

  5. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

  6. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Azficel-T is marketed in the US as Laviv for intradermal injection. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

    Synonyms: Azficel-T
  7. Drug

    Lamotrigine

    go.drugbank.com/drugs/DB00555
    ApprovedInvestigational

    Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. … Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries.

  8. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: INVEGA SUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 25MG, INVEGASUSTENNA® SUSPENSIÓN DE LIBERACIÓN PROLONGADA DE 75 MG
  9. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235384] Ibrexafungerp is orally bioavailable compared to the echinocandins [caspofungin], [micafungin], and [anidulafungin]; which can only be administered parenterally.

  10. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    Polycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. … The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability,